LPAAT-β Double Nickase Plasmid (h): sc-405045-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LPAAT-β Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LPAAT-β Double Nickase Plasmid (h) and LPAAT-β Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting AGPAT2. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LPAAT-β Double Nickase Plasmid (h) | sc-405045-NIC | 20 µg | $410.00 | |||
LPAAT-β Double Nickase Plasmid (h2) | sc-405045-NIC-2 | 20 µg | $410.00 |
AGPAT2 encodes lysophosphatidic acid acyltransferase-β (LPAAT-β), an endoplasmic reticulum–associated enzyme that catalyzes the acylation of lysophosphatidic acid to phosphatidic acid, a central intermediate in glycerophospholipid and triacylglycerol biosynthesis. By controlling phosphatidic acid availability, LPAAT-β influences membrane biogenesis, lipid droplet formation, and lipid signaling nodes that interface with phospholipid remodeling and energy storage pathways. AGPAT2 activity is tightly linked to adipocyte lipid homeostasis and broader metabolic regulation, and disruption of this pathway is associated with severe lipodystrophy phenotypes and insulin resistance–related metabolic dysfunction. As a result, AGPAT2 is frequently studied in contexts of adipogenesis, organelle lipid flux, and lipid-mediated regulation of cellular stress responses.
LPAAT-β Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the AGPAT2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within AGPAT2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt AGPAT2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of AGPAT2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.